Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept?

Drug development research - 1 Nov 2014

Murdaca Giuseppe, Gulli Rossella, Spanò Francesca, Mandich Paola, Puppo Francesco

Abstract excerpt

There are five tumor necrosis factor alpha (TNF-α) inhibitors available for clinical use that have demonstrated efficacy as monotherapy or in combination with other anti-inflammatory or disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of immune-mediated diseases. These include the anti-TNF-α monoclonal antibodies infliximab, adalimumab, golimumab, and certolizumab pegol, and the fusion protein,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents
Share to Arthritis, Rheumatoid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Etanercept

Share to Immunoglobulin G

Share to Lymphotoxin-alpha

Share to Receptors, Tumor Necrosis Factor

Share to Treatment Outcome

Share to Tumor Necrosis Factor-alpha

Source

Identifiers

PMID: 25381983
DOI: 10.1002/ddr.21185

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept?PMID 25381983Read ↗

Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis.Semantic proximity Read ↗

Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy.Semantic proximity Read ↗

Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease.Semantic proximity Read ↗

Predicting response to TNF antagonists in rheumatoid arthritis: the promise of pharmacogenetics research using clinical registries.Semantic proximity Read ↗

Pharmacogenetics: Anti-TNF therapy in RA--towards personalized medicine?Semantic proximity Read ↗

Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?Semantic proximity Read ↗

Genetic and genomic predictors of anti-TNF response.Semantic proximity Read ↗

Genetic and Genomic Markers of Anti-TNF Treatment Response in Rheumatoid ArthritisSemantic proximity Read ↗

Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy.Semantic proximity Read ↗

Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis.Semantic proximity Read ↗

Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.Semantic proximity Read ↗

Exploring pharmacogenetic variants for predicting response to anti-TNF therapy in autoimmune diseases: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.